Login to Your Account



Disappointing news on PI-88 casts shadow over biotech in Taiwan

By Dave Silver
Staff Writer

Thursday, July 31, 2014
TAIPEI, Taiwan – Medigen Biotechnology Corp. said following a meeting Sunday with an independent committee to discuss results midway through the multinational phase III trial for PI-88, the company's adjuvant treatment of hepatocellular carcinoma after surgical resection, preliminary results showed no improvement of survival rates over placebo.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription